Initial testing (stage 1) of the phosphatidylinositol 3′ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program

C. Patrick Reynolds, Min H. Kang, Hernan Carol, Richard Lock, Richard Gorlick, E. Anders Kolb, Raushan T. Kurmasheva, Stephen T. Keir, John M. Maris, Catherine A. Billups, Peter J. Houghton, Malcolm A. Smith

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Activation of the PI3 kinase pathway occurs frequently in many adult cancers and is implicated in tumor cell proliferation, survival, and resistance to chemotherapy and radiotherapy. However, less is known regarding the relevance of this pathway in pediatric cancers. Here we have evaluated SAR245408, a novel small molecule PI3K inhibitor, against childhood cancer cell lines and xenografts. Procedures: SAR245408 was tested against the PPTP in vitro cell line panel at concentrations from 10 to 100μM and against the PPTP in vivo xenograft panels at a dose of 100mg/kg administered orally daily×14. Results: In vitro SAR245408 demonstrated cytotoxic activity, with a median relative IC50 value of 10.9μM (range 2.7-24.5μM). SAR245408 was well tolerated in vivo, and all 44 tested xenograft models were evaluable for efficacy. SAR245408 induced significant differences in EFS distribution compared to control in 29 of 37 (79%) of solid tumor xenografts and in two of seven (29%) ALL xenografts. SAR245408 induced tumor growth inhibition meeting criteria for intermediate EFS T/C activity (EFS T/C>2) in 4 of 37 (11%) solid tumor xenografts. Intermediate EFS T/C activity was also observed for two of seven (29%) evaluable ALL xenografts. Objective responses were not observed for solid tumor or for ALL xenografts. Conclusions: Under the conditions evaluated in this study, SAR245408 achieved modest single-agent activity against most PPTP preclinical models. Further exploration of SAR245408 in combination with standard agents or with other signaling inhibitors could be considered.

Original languageEnglish (US)
Pages (from-to)791-798
Number of pages8
JournalPediatric Blood and Cancer
Volume60
Issue number5
DOIs
StatePublished - May 2013

Fingerprint

Phosphatidylinositol 3-Kinase
Heterografts
Pediatrics
Neoplasms
Phosphatidylinositol 3-Kinases
Cell Line
XL147
Inhibitory Concentration 50
Cell Survival
Radiotherapy
Cell Proliferation
Drug Therapy

Keywords

  • Developmental therapeutics
  • PI3K inhibitor
  • Preclinical testing

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Initial testing (stage 1) of the phosphatidylinositol 3′ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program. / Reynolds, C. Patrick; Kang, Min H.; Carol, Hernan; Lock, Richard; Gorlick, Richard; Kolb, E. Anders; Kurmasheva, Raushan T.; Keir, Stephen T.; Maris, John M.; Billups, Catherine A.; Houghton, Peter J.; Smith, Malcolm A.

In: Pediatric Blood and Cancer, Vol. 60, No. 5, 05.2013, p. 791-798.

Research output: Contribution to journalArticle

Reynolds, CP, Kang, MH, Carol, H, Lock, R, Gorlick, R, Kolb, EA, Kurmasheva, RT, Keir, ST, Maris, JM, Billups, CA, Houghton, PJ & Smith, MA 2013, 'Initial testing (stage 1) of the phosphatidylinositol 3′ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program', Pediatric Blood and Cancer, vol. 60, no. 5, pp. 791-798. https://doi.org/10.1002/pbc.24301
Reynolds, C. Patrick ; Kang, Min H. ; Carol, Hernan ; Lock, Richard ; Gorlick, Richard ; Kolb, E. Anders ; Kurmasheva, Raushan T. ; Keir, Stephen T. ; Maris, John M. ; Billups, Catherine A. ; Houghton, Peter J. ; Smith, Malcolm A. / Initial testing (stage 1) of the phosphatidylinositol 3′ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program. In: Pediatric Blood and Cancer. 2013 ; Vol. 60, No. 5. pp. 791-798.
@article{0d55046b5b4544b2a21f0db2b9a32aeb,
title = "Initial testing (stage 1) of the phosphatidylinositol 3′ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program",
abstract = "Background: Activation of the PI3 kinase pathway occurs frequently in many adult cancers and is implicated in tumor cell proliferation, survival, and resistance to chemotherapy and radiotherapy. However, less is known regarding the relevance of this pathway in pediatric cancers. Here we have evaluated SAR245408, a novel small molecule PI3K inhibitor, against childhood cancer cell lines and xenografts. Procedures: SAR245408 was tested against the PPTP in vitro cell line panel at concentrations from 10 to 100μM and against the PPTP in vivo xenograft panels at a dose of 100mg/kg administered orally daily×14. Results: In vitro SAR245408 demonstrated cytotoxic activity, with a median relative IC50 value of 10.9μM (range 2.7-24.5μM). SAR245408 was well tolerated in vivo, and all 44 tested xenograft models were evaluable for efficacy. SAR245408 induced significant differences in EFS distribution compared to control in 29 of 37 (79{\%}) of solid tumor xenografts and in two of seven (29{\%}) ALL xenografts. SAR245408 induced tumor growth inhibition meeting criteria for intermediate EFS T/C activity (EFS T/C>2) in 4 of 37 (11{\%}) solid tumor xenografts. Intermediate EFS T/C activity was also observed for two of seven (29{\%}) evaluable ALL xenografts. Objective responses were not observed for solid tumor or for ALL xenografts. Conclusions: Under the conditions evaluated in this study, SAR245408 achieved modest single-agent activity against most PPTP preclinical models. Further exploration of SAR245408 in combination with standard agents or with other signaling inhibitors could be considered.",
keywords = "Developmental therapeutics, PI3K inhibitor, Preclinical testing",
author = "Reynolds, {C. Patrick} and Kang, {Min H.} and Hernan Carol and Richard Lock and Richard Gorlick and Kolb, {E. Anders} and Kurmasheva, {Raushan T.} and Keir, {Stephen T.} and Maris, {John M.} and Billups, {Catherine A.} and Houghton, {Peter J.} and Smith, {Malcolm A.}",
year = "2013",
month = "5",
doi = "10.1002/pbc.24301",
language = "English (US)",
volume = "60",
pages = "791--798",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Initial testing (stage 1) of the phosphatidylinositol 3′ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program

AU - Reynolds, C. Patrick

AU - Kang, Min H.

AU - Carol, Hernan

AU - Lock, Richard

AU - Gorlick, Richard

AU - Kolb, E. Anders

AU - Kurmasheva, Raushan T.

AU - Keir, Stephen T.

AU - Maris, John M.

AU - Billups, Catherine A.

AU - Houghton, Peter J.

AU - Smith, Malcolm A.

PY - 2013/5

Y1 - 2013/5

N2 - Background: Activation of the PI3 kinase pathway occurs frequently in many adult cancers and is implicated in tumor cell proliferation, survival, and resistance to chemotherapy and radiotherapy. However, less is known regarding the relevance of this pathway in pediatric cancers. Here we have evaluated SAR245408, a novel small molecule PI3K inhibitor, against childhood cancer cell lines and xenografts. Procedures: SAR245408 was tested against the PPTP in vitro cell line panel at concentrations from 10 to 100μM and against the PPTP in vivo xenograft panels at a dose of 100mg/kg administered orally daily×14. Results: In vitro SAR245408 demonstrated cytotoxic activity, with a median relative IC50 value of 10.9μM (range 2.7-24.5μM). SAR245408 was well tolerated in vivo, and all 44 tested xenograft models were evaluable for efficacy. SAR245408 induced significant differences in EFS distribution compared to control in 29 of 37 (79%) of solid tumor xenografts and in two of seven (29%) ALL xenografts. SAR245408 induced tumor growth inhibition meeting criteria for intermediate EFS T/C activity (EFS T/C>2) in 4 of 37 (11%) solid tumor xenografts. Intermediate EFS T/C activity was also observed for two of seven (29%) evaluable ALL xenografts. Objective responses were not observed for solid tumor or for ALL xenografts. Conclusions: Under the conditions evaluated in this study, SAR245408 achieved modest single-agent activity against most PPTP preclinical models. Further exploration of SAR245408 in combination with standard agents or with other signaling inhibitors could be considered.

AB - Background: Activation of the PI3 kinase pathway occurs frequently in many adult cancers and is implicated in tumor cell proliferation, survival, and resistance to chemotherapy and radiotherapy. However, less is known regarding the relevance of this pathway in pediatric cancers. Here we have evaluated SAR245408, a novel small molecule PI3K inhibitor, against childhood cancer cell lines and xenografts. Procedures: SAR245408 was tested against the PPTP in vitro cell line panel at concentrations from 10 to 100μM and against the PPTP in vivo xenograft panels at a dose of 100mg/kg administered orally daily×14. Results: In vitro SAR245408 demonstrated cytotoxic activity, with a median relative IC50 value of 10.9μM (range 2.7-24.5μM). SAR245408 was well tolerated in vivo, and all 44 tested xenograft models were evaluable for efficacy. SAR245408 induced significant differences in EFS distribution compared to control in 29 of 37 (79%) of solid tumor xenografts and in two of seven (29%) ALL xenografts. SAR245408 induced tumor growth inhibition meeting criteria for intermediate EFS T/C activity (EFS T/C>2) in 4 of 37 (11%) solid tumor xenografts. Intermediate EFS T/C activity was also observed for two of seven (29%) evaluable ALL xenografts. Objective responses were not observed for solid tumor or for ALL xenografts. Conclusions: Under the conditions evaluated in this study, SAR245408 achieved modest single-agent activity against most PPTP preclinical models. Further exploration of SAR245408 in combination with standard agents or with other signaling inhibitors could be considered.

KW - Developmental therapeutics

KW - PI3K inhibitor

KW - Preclinical testing

UR - http://www.scopus.com/inward/record.url?scp=84874999558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874999558&partnerID=8YFLogxK

U2 - 10.1002/pbc.24301

DO - 10.1002/pbc.24301

M3 - Article

C2 - 23002019

AN - SCOPUS:84874999558

VL - 60

SP - 791

EP - 798

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 5

ER -